COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
United States Public Health Service, Atlanta, GA, USA.
Clin Infect Dis. 2021 Dec 6;73(11):e4141-e4151. doi: 10.1093/cid/ciaa1459.
Coronavirus disease (COVID-19) can cause severe illness and death. Predictors of poor outcome collected on hospital admission may inform clinical and public health decisions.
We conducted a retrospective observational cohort investigation of 297 adults admitted to 8 academic and community hospitals in Georgia, United States, during March 2020. Using standardized medical record abstraction, we collected data on predictors including admission demographics, underlying medical conditions, outpatient antihypertensive medications, recorded symptoms, vital signs, radiographic findings, and laboratory values. We used random forest models to calculate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for predictors of invasive mechanical ventilation (IMV) and death.
Compared with age <45 years, ages 65-74 years and ≥75 years were predictors of IMV (aORs, 3.12 [95% CI, 1.47-6.60] and 2.79 [95% CI, 1.23-6.33], respectively) and the strongest predictors for death (aORs, 12.92 [95% CI, 3.26-51.25] and 18.06 [95% CI, 4.43-73.63], respectively). Comorbidities associated with death (aORs, 2.4-3.8; P < .05) included end-stage renal disease, coronary artery disease, and neurologic disorders, but not pulmonary disease, immunocompromise, or hypertension. Prehospital use vs nonuse of angiotensin receptor blockers (aOR, 2.02 [95% CI, 1.03-3.96]) and dihydropyridine calcium channel blockers (aOR, 1.91 [95% CI, 1.03-3.55]) were associated with death.
After adjustment for patient and clinical characteristics, older age was the strongest predictor of death, exceeding comorbidities, abnormal vital signs, and laboratory test abnormalities. That coronary artery disease, but not chronic lung disease, was associated with death among hospitalized patients warrants further investigation, as do associations between certain antihypertensive medications and death.
冠状病毒病(COVID-19)可导致严重疾病和死亡。入院时收集的不良预后预测因素可能为临床和公共卫生决策提供信息。
我们对 2020 年 3 月在美国佐治亚州的 8 所学术和社区医院住院的 297 名成年人进行了回顾性观察队列研究。我们使用标准化病历摘录收集了预测因素的数据,包括入院人口统计学、基础医疗条件、门诊抗高血压药物、记录的症状、生命体征、影像学结果和实验室值。我们使用随机森林模型计算了侵入性机械通气(IMV)和死亡的预测因素的调整后优势比(aOR)和 95%置信区间(CI)。
与年龄<45 岁相比,年龄 65-74 岁和≥75 岁是 IMV 的预测因素(aORs,3.12[95%CI,1.47-6.60]和 2.79[95%CI,1.23-6.33]),也是死亡的最强预测因素(aORs,12.92[95%CI,3.26-51.25]和 18.06[95%CI,4.43-73.63])。与死亡相关的合并症(aORs,2.4-3.8;P<.05)包括终末期肾病、冠状动脉疾病和神经障碍,但不包括肺部疾病、免疫功能低下或高血压。与非使用相比,院前使用血管紧张素受体阻滞剂(aOR,2.02[95%CI,1.03-3.96])和二氢吡啶钙通道阻滞剂(aOR,1.91[95%CI,1.03-3.55])与死亡相关。
在调整了患者和临床特征后,年龄较大是死亡的最强预测因素,超过了合并症、异常生命体征和实验室检查异常。在住院患者中,冠状动脉疾病而不是慢性肺部疾病与死亡相关,这值得进一步研究,抗高血压药物与死亡之间的关联也是如此。